Why the study?
Does 2,3-butanedione monoxime (BDM) protect isolated rat hearts from ischemia-reperfusion injury?
Does 2,3-butanedione monoxime (BDM) protect isolated rat hearts from ischemia-reperfusion injury?
BDM protects isolated rat hearts from ischemia-reperfusion injury; leaves open translation to clinical cardioprotection.
Protection of the ischemic myocardium by pretreatment with a high dose of 2,3-butanedione monoxime (BDM) is attributed to the enhancement of glycolytic ATP production rather than to the inhibition of contracture during mild ischemia. Our objective was to investigate whether the inhibition of contracture would protect the arrested heart during prolonged ischemia. Isolated perfused rat hearts were subjected to 30 min of low-flow ischemia followed by reperfusion. Ischemic hearts were treated with BDM (5 mmol/l) after beating stopped. BDM ameliorated the increase in intraventricular pressure after ischemia without significant changes in ATP levels and with a decreased accumulation of lactate. BDM treatment accelerated the recovery of function and high-energy phosphates with reduced myocardial Ca2+ overload. The results of this study suggested that inhibition of contracture can protect the heart from ischemia-reperfusion injury.
No takes yet. Share an insight, caveat, or question.
Tani et al. (1996) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: